This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pediatrix's (MD) Q4 Earnings Miss Due to Soft Patient Volumes
by Zacks Equity Research
Pediatrix's (MD) Q4 results were hit by an increase in overall cost level resulting from higher same-unit clinical compensation costs. Yet, an impressive 2024 adjusted EBITDA guidance is likely to provide relief to investors.
Zacks Industry Outlook Highlights Cigna, Centene and Molina Healthcare
by Zacks Equity Research
Cigna, Centene and Molina Healthcare have been highlighted in this Industry Outlook article.
3 HMO Stocks in Focus Despite High Tech Costs & Nursing Shortage
by Debasmita Chatterjee
Growing customer base and M&A strategies are likely to aid the Medical-HMO industry. However, escalating expenses and a dearth in the availability of medical personnel are concerning. Stocks like CI, CNC and MOH are likely to navigate the industry storms.
Stock Market News for Feb 9, 2024
by Zacks Equity Research
Wall Street closed higher on Thursday as strong earnings data boosted market participants¿¿¿ confidence on risky assets like equities.
Molina Healthcare (MOH) Q4 Earnings Beat on Premium Growth
by Zacks Equity Research
Molina Healthcare (MOH) expects adjusted EPS to be at a minimum of $23.5 in 2024, which represents a year-over-year improvement of 12.5%.
Here's Why Molina (MOH) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Molina (MOH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Molina (MOH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Molina (MOH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 1.62% and 8.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.
Gear Up for Molina (MOH) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Molina (MOH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Cigna (CI) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 4.14% and 4.77%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pick These 4 Stocks With Amazing Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOH, ATO, AMZN and OPCH are sound enough to meet financial obligations.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Molina Healthcare, Inc (MOH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Molina (MOH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Molina Healthcare (MOH) Up 26.9% in 6 Months: What Lies Ahead?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to keep growing on the back of increases in investment income and Medicare premiums.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Should Value Investors Buy Centene (CNC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Strength Seen in Select Medical (SEM): Can Its 11.3% Jump Turn into More Strength?
by Zacks Equity Research
Select Medical (SEM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
The Zacks Analyst Blog Highlights UnitedHealth, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, Humana, Centene and Molina Healthcare are included in this Analyst Blog.
4 Health Insurers Likely to Maintain Winning Streak in 2024
by Debasmita Chatterjee
Medical-HMO stocks like UNH, HUM, CNC and MOH are expected to reap the benefits of an aging U.S. population and growing premiums in 2024. However, challenges related to the resumption of elective procedures might play spoilsport.
Molina (MOH) to Pay Lower Price for California Medicare Buyout
by Zacks Equity Research
Molina Healthcare's (MOH) new price for Bright HealthCare's California Medicare business constitutes 23% of the anticipated $1.8 billion premium revenues for 2023.
Why Molina (MOH) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is Humana (HUM) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.